This study establishes this engineered AAV as a versatile and potent vaccine platform that effectively targets DCs, offering a promising approach for inducing robust and adaptable anti-tumor immunity.
Abstract
Background The clinical efficacy of therapeutic cancer vaccines is critically limited by the inefficient in vivo delivery of tumor antigens to dendritic cells (DCs), the key regulators of T-cell immunity. Methods To address this issue, we developed a dendritic-cell-targeting adeno-associated virus (AAV) vector through rational capsid design. This was achieved by site-specifically inserting the high-affinity Clec9a-targeting peptide CBP-12, optimizing its flanking sequences, and introducing T491V/S662V gain-of-function mutations to synergistically enhance DC transduction. Results The resulting vector, AAV2-mut-Peptide2, showed significantly improved tropism for and gene delivery efficiency to cross-presenting cDC1s in vivo. In murine models of hepatocellular carcinoma, vaccination with this platform, encoding either a model antigen (OVA) or the endogenous tumor-associated antigen GPC3, elicited a potent antigen-specific CD8+ T cell response. This response was characterized by a substantial increase in tumor-infiltrating lymphocytes, enhanced production of key effector cytokines, and consequently, potent suppression of tumor growth. Conclusion Our study establishes this engineered AAV as a versatile and potent vaccine platform that effectively targets DCs, offering a promising approach for inducing robust and adaptable anti-tumor immunity.
Adenoviral vectors have been widely validated as effective vaccine platforms for both infectious diseases and cancer due to their strong immunostimulatory properties. However, their application to personalized cancer vaccines and other time-sensitive antigens is limited by the prolonged production time required for c...
Jia-Bao Han, E. Kashentseva, Igor P. Dmitriev et al.· ACS Nano· 0 citations
It is demonstrated that site-selective CD3scFv insertion into a single AAV capsid protein provides a robust, versatile platform for improved T cell transduction and effective in vivo CAR-T cell generation, offering a promising off-the-shelf approach for treating B cell malignancies.
Hai-Feng Chen, T. Hoang, A. Smith et al.· Molecular Therapy· 0 citations
The biological rationale for DC-directed immunotherapy, tumor-induced DC dysfunction, next-generation DC platforms, in vivo DC targeting, DC-derived extracellular vesicles, negative and controversial clinical evidence, and rational combinations with checkpoint blockade and tumor-microenvironment-modulating strategies a...
Serena Zanotta, Domenico Galati· International Journal of Mol...· 0 citations
Dendritic cells (DCs) coordinate antigen presentation and immune-effector activation, but vaccine-induced immune responses have not consistently translated into clinical benefit. This focused narrative review evaluates therapeutic vaccination in established pancreatic cancer and potential adjuvant use after resection,...